Cellectis opens labs and offices in New York
9 April 2015 | By Victoria White
Cellectis has established a new subsidiary, Cellectis, Inc. in New York City. The U.S. headquarters includes large state-of-the-art research laboratories...
List view / Grid view
9 April 2015 | By Victoria White
Cellectis has established a new subsidiary, Cellectis, Inc. in New York City. The U.S. headquarters includes large state-of-the-art research laboratories...
9 April 2015 | By Caroline Richards, Editor, Drug Target Review
In this NGS In-Depth Focus; How next-generation sequencing came to be, plus a brief history & Data management for large-scale NGS-based research projects...
Tim Hammonds from Cancer Research Technology Discoveries explains how academic HTS laboratories came into being and outlines the challenges facing the new HTS model...
Wolfgang Fecke and Christine Williams from UCB discuss the industry’s approach to drug discovery with costs escalating and output failing to achieve the corresponding increases in revenue...
In his fascinating overview of label-free analysis, Dr. Masson introduces the four main label-free methods: physical, electrochemical, mass-based and optical techniques, before providing the reader with in-depth insight into the most common label-free technique within the pharmaceutical industry: surface plasmon resonance (SPR)...
This article evaluates a GADD45a-GFP human cell assay for rapid and reliable in vitro early genotoxicity screening...
Preview of the upcoming foreword in our April issue, written by Sheraz Gul, Vice President and Head of Biology at Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Hamburg, Germany...
We discuss the steps required for differentiating human pluripotent stem cells into hepatocyte-like cells, and how long this process takes and the quality control measures needed...
Sheraz Gul, Head of Biology at Fraunhofer-IME SP, provides an in-depth review of the Cell-Based Assays for Screening workshop which took place in December 2014...
7 April 2015 | By Victoria White
Nabriva, a biotechnology company focused on developing pleuromutilins, has announced the successful completion of a $120 million Series B financing...
7 April 2015 | By Victoria White
PhoreMost, a biopharmaceutical company focused on increasing diversity of novel therapeutics, has been founded to identify new druggable targets for cancer...
2 April 2015 | By Victoria White
PeptiDream Inc. has announced that Novartis has exercised its option to obtain a nonexclusive license to the Peptide Discovery Platform System technology...
2 April 2015 | By Victoria White
Merck Serono and MMV have announced that an agreement has been signed for Merck Serono to obtain the rights to the antimalarial compound DDD107498...
1 April 2015 | By Victoria White
A consortium will collaborate with Basilea to progress a new family of cancer drugs designed to block several key cancer-causing proteins at once...
31 March 2015 | By Victoria White
Selvita announced today that it is commencing IND-enabling studies for SEL24 project, the company’s first oncology drug candidate...